This new treatment provides adults living with schizophrenia a long-acting formulation that offers flexible 1- and 2-month dosing intervals1
In a Phase 3 clinical trial, UZEDY demonstrated up to. | April 28, 2023
This new treatment provides adults living with schizophrenia a long-acting formulation that offers flexible 1- and 2-month dosing intervals1 In a Phase 3 clinical trial, UZEDY demonstrated
For older patients with resistant depression who fail to respond to antidepressants, the addition of atypical antipsychotic aripiprazole is superior to switching antidepressants, new research suggests.
Most antipsychotics have weight-related and metabolic side effects. This study shines a light on the relationship of dose and weight for each agent to help inform which antipsychotic to prescribe.